Ivo Veletic, M.D.

Peer-Reviewed Articles

1. Dasdemir E, Veletic I, Ly CP, Quesada AE, Pacheco CD, Jelloul FZ, Borges P, Basu S, Jindal S, Wang Z, Lazar A, Wani KM, Antunes DA, Reville PK, Gunaratne PH, Tower RJ, Sharma P, Abbas HA. Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML. iScience, 2026. e-Pub 2026. PMID: 41536977.
2. Ferri-Borgogno S, Stolley DL, Gamal BT, Pacheco CD, Veletic I, Basi A, Mak DH, McAllister MK, Lin AJ, Gomez JA, Casasent AK, Burks JK. Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry. J Vis Exp, 2025. e-Pub 2025. PMID: 41325369.
3. Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo YA, Garza AI, Root JL, Qiao W, Arruda A, Veletic I, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau SM, Minden MD, Ravandi F, Kantarjian HM, Abbas HA. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood 145(25):3015-3029, 2025. e-Pub 2025. PMID: 40179376.
4. Veletic I, Harris DM, Rozovski U, Bertilaccio MTS, Calin G, Takahashi K, Li P, Liu Z, Manshouri T, Drula RC, Furudate K, Muftuoglu M, Hossain A, Wierda WG, Keating MJ, Estrov Z. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia 39(6):1380-1394, 2025. e-Pub 2025. PMID: 40186065.
5. Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi AV, Gomez JA, Root JL, Reville PK, Jindal S, Basu S, Sharma P, Quesada AE, Bueso-Ramos C, Manshouri T, Cuglievan B, Garcia M, Burks JK, Abbas HA. Multimodal spatial proteomic profiling in acute myeloid leukemia. NPJ Precis Oncol 9(1):148, 2025. e-Pub 2025. PMID: 40394148.
6. Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia M, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
7. Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J, Mesa R, Pozdnyakova O, Ritchie E, Veletic I, Gamel K, Hamidi H, Han L, Higgins B, Trunzer K, Uguen M, Wang D, El-Galaly TC, Todorov B, Gotlib J. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica 108(10):2730-2742, 2023. e-Pub 2023. PMID: 37165840.
8. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
9. Manshouri T, Veletic I, Li P, Yin CC, Post SM, Verstovsek S, Estrov Z. GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis 13(5):481, 2022. e-Pub 2022. PMID: 35595725.
10. Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica 106(9):2384-2396, 2021. e-Pub 2021. PMID: 32732359.
11. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
12. Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One 14(9):e0222912, 2019. e-Pub 2019. PMID: 31569199.
13. Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood 133(21):2320-2324, 2019. e-Pub 2019. PMID: 30745304.
14. Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R. Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr 130(3-4):126-133, 2018. e-Pub 2018. PMID: 29372410.
15. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
16. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
17. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.

Abstracts

1. Baran N, Lodi A, Patel S, Ortiz JE, Collins M, Sharma P, Mohanty V, Dede M, Veletic I, Ramage CL, Park JH, Dhungana Y, Skwarska A, Zhou Y, Zeng Z, Weng C, Hayes K, Alatrash G, Dunner K, Marszalek JR, Borthakur G, Yu J, Thandapani P, Davis R, Kaipparettu BA, Chen K, Bhattacharya PK, Tiziani S, Konopleva M. CRISPR-Cas9 screen-driven identification of metabolic vulnerabilities reveals synthetic lethality via synergistic targeting of mitochondrial energy pathways and lactate export in oxphosdependent T-ALL. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
2. Muftuoglu M, Muftuoglu M, Singh S, Singh S, Bedoy A, Bedoy A, Li L, Li L, Basyal M, Basyal M, Dipmoy N, Dipmoy N, Ostermann L, Ostermann L, Veletic I, Veletic I, Pacheco C, Pacheco C, Mak PY, Mak PY, Ayoub E, Ayoub E, Kim T, Kim T, Garland K, Garland K, Pierce R, Pierce R, Angel M, Angel M, Luther S, Luther S, Rohde C, Rohde C, Andreeff M, Andreeff M. Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
3. Veletic I, Manshouri T, Pacheco C, Ly C, Yin CC, Burks J, Pemmaraju N, Masarova L, Bose P, Abbas H, Dunbar A. Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
4. Okeleji O, Singh S, Bedoy A, Ostermann L, Garland KM, Mak PY, Pacheco C, Ayoub E, Veletic I, Angel M, Luther S, Rohde C, Andreeff M. iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
5. Singh S, Bedoy A, Muftuoglu M, Li L, Okeleji O, Dipmoy N, Ostermann L, Veletic I, Pacheco C, Basyal M, Kim T, Garland KM, Angel M, Luther S, Rohde C, Andreeff M, Anand V. Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
6. Nguyen AH, Xiao W, Veletic I, Manshouri T, Braish J, El Hajjar G, Issa G, Pemmaraju N, Masarova L, Bose P, Abbas H. Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
7. Xiao W, Nguyen AH, Veletic I, Manshouri T, Pemmaraju N, Masarova L, Bose P, Abbas H. Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
8. Muftuoglu M, Singh S, Bedoy AD, Li L, Nath D, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Basyal M, Kim T, Luther S, Rohde CB, Andreeff M. Gene-modified iPS-derived MSC restore a ‘Hot’ immune microenvironment in high-grade serous ovarian cancer. AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research 85(18_Supplement):PR001, 2025. e-Pub 2025.
9. Bose P, Pemmaraju N, Masarova L, Veletic I, Abbas H, Kornblau S, Maiti A, Jain N, Manshouri T, Wang X, Pinsoy M, Pierce S, Zhou L, Dobbins M, Kantarjian H, Estrov Z, Verstovsek S. Final results of a pilot study of elotuzumab in patients with myelofibrosis. 30th EHA Congress, 2025. e-Pub 2025.
10. Singh S, Bedoy AD, Muftuoglu M, Nath D, Li L, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Basyal M, Kim T, Luther S, Rohde CB, Andreeff M. Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a" cold" ovarian tumor model. 2025 ASCO Annual Meeting 43(16_suppl):2538, 2025. e-Pub 2025.
11. Singh S, Bedoy A, Nath D, Chang KH, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Muftuoglu M, Basyal M, Kim T, Hinkel RD, Garland KM, Angel M, Luther S, Rohde CB, Andreeff M. iPS-derived MSC secreting IL7 and IL15 exert immune mediated anti-tumor activities. AACR Annual Meeting 2025 85(8_Supplement_1):3473, 2025. e-Pub 2025.
12. Veletic I, Manshouri T, Yin CC, Pacheco CD, Ly CP, Dasdemir E, Cohen EN, Masarova L, Pemmaraju N, Bose P, Kantarjian HM, Estrov Z, Reville PK, Dunbar A, Abbas H. Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis. 66th ASH Annual Meeting and Exposition 144(Suppl 1):1760, 2024. e-Pub 2024.
13. Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi A, Gomez JA, Root JL, Reville PK, Quesada AE, Bueso-Ramos CE, Garcia MB, Burks JK, Abbas HA. Multimodal Spatial Profiling in Acute Myeloid Leukemia. 66th ASH Annual Meeting and Exposition 144(Suppl 1):2681, 2024. e-Pub 2024.
14. Abbas HA, Nguyen A, Wang B, Chen M, Yang G, Lampson B, Erlich RL, Veletic I. Blood-Based Proteomics for Deeper Insights into Indolent Systemic Mastocytosis: The Pioneer Trial Experience. 66th ASH Annual Meeting and Exposition 144(Suppl 1):6569, 2024. e-Pub 2024.
15. Dasdemir E, Veletic I, Ly CP, Quesada AE, Jelloul FZ, Borges P, Basu S, Jindal S, Wang Z, Lazar AJ, Wani KM, Antunes DA, Reville PK, Gunaratne P, Tower RJ, Sharma P, Abbas HA. Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia. 66th ASH Annual Meeting and Exposition 144(Suppl 1):1059, 2024. e-Pub 2024.
16. Wang B, Reville PK, Jelloul FZ, Desai PN, Borges P, Ly C, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Vaugh N, Baran N, Deng Q, Matthews J, Gunaratne P, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva MY, Futreal A, Post SM, Abbas HA. IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. 65th ASH Annual Meeting and Exposition 142(Suppl 1):2796, 2023. e-Pub 2023.
17. Veletic I, Harris DM, Rozovski U, Li P, Liu Z, Manshouri T, Bertilaccio MTS, Calin GA, Drula RC, Takahashi K, Furudate K, Muftuoglu M, Hossain A, Ferrajoli A, Burger JA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. 65th ASH Annual Meeting and Exposition 142(Suppl 1):3264, 2023. e-Pub 2023.
18. Veletic I, Manshouri T, Pacheco CD, Yin CC, Zhang Y, Li P, Cohen EN, Gomez JA, Burks JK, Verstovsek S, Estrov Z. Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis. 65th ASH Annual Meeting and Exposition 142(Suppl 1):4516, 2023. e-Pub 2023.
19. Bose P, Masarova L, Pemmaraju N, Dobbins M, Jain N, Abbas H, Kornblau S, Maiti A, Veletic I, Manshouri T, Bledsoe S, Richie MA, Hall-Moore N, Zhou L, Wang X, Kantarjian H, Estrov Z, Verstovsek S. A pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis. 28th EHA Congress 7(S3):e5738496, 2023. e-Pub 2023.
20. Ferri-Borgogno S, Gomez JA, Veletic I, Burks JK, Mok SC. Depicting spatially-resolved immune landscapes in long-term ovarian cancer survivors by imaging mass cytometry. AACR Special Conference: Tumor Immunology and Immunotherapy 10(Suppl 12):B31, 2022. e-Pub 2022.
21. Rozovski U, Harris D, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating M, Estrov Z. STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells. SOHO 2021 Annual Meeting 21(Suppl 1):S322-S323, 2021. e-Pub 2021.
22. Veletic I, Manshouri T, Li P, Yin CC, Post S, Verstovsek S, Estrov Z. GLI1 Promotes the Pro-Fibrotic Function of Monocyte-Derived Fibrocytes in Myelofibrosis. SOHO 2021 Annual Meeting 21(Suppl 1):230, 2021. e-Pub 2021.
23. Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZE. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. 61st ASH Annual Meeting and Exposition 134(Suppl 1):3024, 2019. e-Pub 2019.
24. Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZE. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. 61st ASH Annual Meeting and Exposition 134(Suppl 1):3018, 2019. e-Pub 2019.
25. Manshouri T, Veletic I, Zhang Y, Bove JE IV, Li P, Harris DM, Liu Z, Cohen EN, Verstovsek S, Estrov ZE. STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes. 61st ASH Annual Meeting and Exposition 134(Suppl 1):2961, 2019. e-Pub 2019.
26. Yuan B, Ly S, Veletic I, Maldonado K, Zhou X, deCrombrugghe B, Andreeff M, Battula VL. Acute myeloid leukemia cells induce new bone formation by expanding osteoprogenitor niche in the bone marrow. AACR Annual Meeting 2019 79(Suppl 13):2040, 2019. e-Pub 2019.
27. Veletic I, Manshouri T, Nogueras González GM, Prijic S, Bove JE IV, Zhang Y, Verstovsek S, Estrov ZE. PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition. 60th ASH Annual Meeting and Exposition 132(Suppl 1):5487, 2018. e-Pub 2018.
28. Verstovsek S, Hasserjian RP, Pozdnyakova O, Veletic I, Mesa RA, Foltz L, Mascarenhas J, Ritchie EK, Palmer J, Silver RT, Kremyanskaya M, van den Blink B, Gupta R, Manshouri T, Yin CC, Estrov ZE, Gotlib JR. PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. 60th ASH Annual Meeting and Exposition 132(Suppl 1):686, 2018. e-Pub 2018.
29. Manshouri T, Veletic I, Yin CC, Chen L, Bove JE IV, Zhang Y, Verstovsek S, Estrov ZE. Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis. 60th ASH Annual Meeting and Exposition 132(Suppl 1):1793, 2018. e-Pub 2018.
30. Veletic I, Manshouri T, Newberry KJ, Bove JE, Zhang Y, Estrov Z, Verstovsek S. Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis. 59th ASH Annual Meeting and Exposition 130(Suppl 1):5284, 2017. e-Pub 2017.
31. Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. 59th ASH Annual Meeting and Exposition 130(Suppl 1):1728, 2017. e-Pub 2017.
32. Veletic I, Manshouri T, Yin CC, Newberry KJ, Verstovsek S, Estrov Z. Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis. 59th ASH Annual Meeting and Exposition 130(Suppl 1):1664, 2017. e-Pub 2017.
33. Veletic I, Manshouri T, Prijic S, Yin CC, Bove JE IV, Zhang Y, Verstovsek S, Estrov Z. Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis. 58th ASH Annual Meeting and Exposition 128(22):4280, 2016. e-Pub 2016.
34. Prijic S, Manshouri T, Veletic I, Newberry KJ, Zhang Y, Bove JE IV, Estrov Z, Verstovsek S. Loss of Normal T-Cell Subset Distribution in Myelofibrosis Is Recovered By the Immunomodulatory Effects of JAK1/2 Inhibition. 58th ASH Annual Meeting and Exposition 128(22):3138, 2016. e-Pub 2016.
35. Prijic S, Manshouri T, Zhang Y, Veletic I, Zhang X, Bove IV JE, Estrov Z, Verstovsek S. Ruxolitinib Treatment Induces a Transition of Classical to Non-Classical Monocytes in Patients with Myelofibrosis. 57th ASH Annual Meeting and Exposition 126(23):2838, 2015. e-Pub 2015.
36. Andreeff M, Singh S, Bedoy A, Muftuoglu M, Li L, Anand V, Nath D, Ostermann LB, Veletic I, Pacheco CD, Basya M, Kim T, Garland KM, Angel M, Luther S, Pierce R, Rohde CB. Engineered IL7/IL15 Secreting iPSC-Derived Mesenchymal Stromal Cells Convert the Immunosuppressive into Immune-Activated Tumor Microenvironments (TME) and Potentiate Antitumor Immunity. AACR Annual Meeting 2026.
37. Kuo YA, Dasdemir E, Rebboah E, Veletic I, Wang B, Maiti A, Swaminathan M, Konopleva M, Jelloul FZ, Abbas HA. Optimization of a Xenium-based spatial transcriptomics workflow for bone marrows in hematologic malignancies. 2026 Single-Cell Cancer Biology GRC.
38. Rebboah E, Kuo YA, Nguyen AH, Hachem M, Veletic I, Xiao W, Manshouri T, Pemmaraju N, Masarova L, Bose P, Marvin-Peek J, Abbas HA. Spatial transcriptomic dissection of a rare mast cell-driven bone marrow disease. 2026 Single-Cell Cancer Biology GRC.
39. Rebboah E, Xiao W, Nguyen AH, Hachem M, Campoverde L, Veletic I, Manshouri T, Pemmaraju N, Masarova L, Bose P, Marvin-Peek J, Abbas HA. Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis. AIM 2026 Physician and Investigator Conference.
40. Marvin-Peek J, Nguyen AH, Campoverde L, Rebboah E, Xiao W, Hachem M, Veletic I, Manshouri T, Braish J, El Hajjar G, Issa G, Pemmaraju N, Masarova L, Bose P, Abbas HA. Integrated Clinical and Molecular Registry with Longitudinal Biorepository in Systemic Mastocytosis: A Single-Institution Resource. AIM 2026 Physician and Investigator Conference.

Letters to the Editor

1. Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol 185: 382-386, 2019.

Patents

1. Estrov Z, Verstovsek S, Manshouri T, Veletic I. Production of megakaryocytes or platelets from monocytes, 2025. Patent Number: US 12,357,659.